Fri, February 20, 2009
Thu, February 19, 2009
[ Thu, Feb 19th 2009 ] - Market Wire
Enzon Reports 2008 Results
Wed, February 18, 2009
Tue, February 17, 2009
Mon, February 16, 2009
Fri, February 13, 2009
Thu, February 12, 2009
Wed, February 11, 2009
Tue, February 10, 2009
Mon, February 9, 2009
Sun, February 8, 2009
Fri, February 6, 2009
Thu, February 5, 2009
Wed, February 4, 2009

Synta Pharmaceuticals to Present at the ROTH Capital Partners 21st Annual OC Growth Stock Conference


//health-fitness.news-articles.net/content/2009/ .. ners-21st-annual-oc-growth-stock-conference.html
Published in Health and Fitness on Wednesday, February 11th 2009 at 6:01 GMT, Last Modified on 2009-02-11 06:02:25 by Market Wire   Print publication without navigation


LEXINGTON, Mass.--([ BUSINESS WIRE ])--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Company will be presenting at the Roth Capital OC Growth Stock Conference on Tuesday, February 17 at 4:30 p.m. (PST) at the Ritz-Carlton Laguna Niguel, California.

A live audio webcast and replay of the presentation will be available on the "Investors" section of the Company's website, [ www.syntapharma.com ].

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using our compound library and discovery capabilities. Synta has a partnership with GlaxoSmithKline for the joint development and commercialization of its lead investigational drug candidate, elesclomol, which has completed enrollment in a global, pivotal Phase 3 clinical trial for the treatment of metastatic melanoma. For more information, please visit [ www.syntapharma.com ].


Publication Contributing Sources

Similar Health and Fitness Publications